Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase – Here’s What Happened

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw strong trading volume on Wednesday . 3,050,342 shares were traded during mid-day trading, an increase of 39% from the previous session’s volume of 2,196,948 shares.The stock last traded at $39.8050 and had previously closed at $39.72.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Eli Lilly agreed to buy Centessa for $38 per share in cash plus a contingent value right (CVR) that can add up to $9, valuing the transaction at up to $7.8B. The takeover news drove an initial surge in CNTA shares. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Bullish options flow around the announcement — traders bought a large number of call options on March 31 (about 2,994 calls), indicating speculative/transaction-driven upside interest tied to the Lilly bid and potential deal outcomes. (internal trading data)
• Neutral Sentiment: Deal economics and structure — the headline $38 cash upfront values Centessa at roughly $6.3B initially, with the CVR creating upside tied to undisclosed milestones (up to $9 per share). That structure leaves some outcome risk pending milestone achievement and CVR terms. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Negative Sentiment: Analyst downgrades are pressuring the stock today — Needham, Wolfe Research and Stephens cut ratings (to hold), which often trims momentum after a takeover pop and can weigh on short‑term trading. Needham downgrades Centessa Pharmaceuticals plc – depositary receipt (CNTA)
• Negative Sentiment: Large put buying today — unusually heavy purchase of 10,659 put options (a +1,668% spike vs. typical), signaling hedging or bearish bets that can amplify downward pressure if traders roll positions or raise supply. (internal trading data)
• Negative Sentiment: Shareholder litigation and fairness probes — multiple law firms have launched investigations into whether the $38 offer is fair and whether the sale process was adequate; potential legal challenges or demands for a higher bid could prolong uncertainty. Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process
• Negative Sentiment: Recent earnings miss — Centessa reported an EPS miss for the latest quarter (‑$0.48 vs. consensus ‑$0.38), which weakens the company’s standalone fundamentals and gives critics leverage in fairness arguments. (internal earnings data)

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CNTA. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Finally, Oppenheimer upped their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Down 0.3%

The stock’s 50-day moving average price is $26.29 and its two-hundred day moving average price is $25.24. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $5.78 billion, a P/E ratio of -21.64 and a beta of 1.55.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10). As a group, research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider directly owned 57,645 shares in the company, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This represents a 39.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. TD Waterhouse Canada Inc. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter worth about $36,000. T. Rowe Price Investment Management Inc. grew its holdings in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $100,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.